Brief: Lianbio Doses First Patient In Phase 3 Libra Trial Of Tp-03 In Chinese Patients With Demodex Blepharitis

LianBio

01/11/2022 22:24

Nov 1 (Reuters) - LianBio  LIAN.O :
    * LIANBIO DOSES FIRST PATIENT IN REGISTRATIONAL PHASE 3
LIBRA
TRIAL OF TP-03 IN CHINESE PATIENTS WITH DEMODEX BLEPHARITIS
    * LIANBIO - TOPLINE RESULTS EXPECTED IN Q4 OF 2023

Source text for Eikon:  ID:nGNX9G8bLL 
Further company coverage:  LIAN.O 
 ((Reuters.Briefs@thomsonreuters.com;))